Business
Cerus develops and commercializes the INTERCEPT Blood System to reduce blood-borne pathogens in donated blood components used for transfusion.
Cerus grew revenue and narrowed losses, but FCF nearly disappeared and insiders mostly sold.
The read at a glance✓ Audited against SEC data
- Business mix — Blood-safety productsNote
- Revenue — $233.8M, +16.1%OK
- Net loss — ($15.6M), narrowerWatch
- FCF — $1.1M, -87.0%Note
- Equity — $64.2M, +14.4%OK
- Insiders — 1 purchase and 14 salesWatch
- Accounting — Altman weak; Beneish clean; EQ safeWatch
Where the revenue comes from
Fiscal 2025, as CERUS CORP reports it. History and quarterly detail are in the app.
- Product$206.1M
- Government Contract$27.7M
Leadership changes
From CERUS CORP's own filings, the day they're filed.
- Vivek Jayaraman · President · appointmenteff. 2026-07-01
- William M. Greenman · Chief Executive Officer · departureeff. 2025-06-20
- Gail Schulze · directors · departureeff. 2025-02-02
Latest filings
- 8-K · Company announcement2026-07-30
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-07-10
- 8-K · Company announcement2026-06-08
- 8-K · Company announcement2026-06-03
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CERUS CORP, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.